Effect of Eribulin on Patients with Metastatic Breast Cancer: Multicenter Retrospective Observational Study in Taiwan

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2018 Apr 7

PMID 29623575

Citations 5

Authors

Kun-Ming Rau

Fu Ou-Yang

Ta-Chung Chao

Yao-Lung Kuo

Tsui-Fen Cheng

Tsu-Yi Chao

Dar-Ren Chen

Yen-Dun Tzeng

Being-Whey Wang

Chun-Yu Liu

Ming-Hung Hu

Yin-Che Lu

Wei-Jen Ou

Chin-Ho Kuo

Chieh-Han Chuang

Jung-Yu Kan

Fang-Ming Chen

Ming-Feng Hou

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer.

Methods: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer.

Results: The survival rate at 24 months was 57.2% (95% CI 51.0-62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45-3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients' tumors with the luminal A subtype had a significantly better objective response rate. Kaplan-Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events.

Conclusions: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.

Citing Articles

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study.

Jafri M, Kristeleit H, Misra V, Baxter M, Ahmed S, Jegannathen A Oncology. 2022; 100(12):666-673.

PMID: 36044833 PMC: 9808648. DOI: 10.1159/000526140.

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study.

Liu C, Hsieh M, Su Y, Hung C, Pei S, Liao C J Cancer. 2021; 12(17):5355-5364.

PMID: 34335952 PMC: 8317530. DOI: 10.7150/jca.60682.

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.

Zhao Y, Xie N, Li W, Chen W, Lv Z, Zheng Y Ther Adv Med Oncol. 2021; 13:17588359211030210.

PMID: 34290830 PMC: 8274129. DOI: 10.1177/17588359211030210.

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK).

Park M, Lee S, Noh W, Jeon C, Lee S, Son G Breast. 2020; 54:121-126.

PMID: 32980648 PMC: 7519365. DOI: 10.1016/j.breast.2020.09.004.

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.

Inoue K, Takahashi M, Mukai H, Yamanaka T, Egawa C, Sakata Y Invest New Drugs. 2020; 38(5):1540-1549.

PMID: 31950374 PMC: 7497681. DOI: 10.1007/s10637-019-00890-5.

References

Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I . Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J Cancer. 2014; 5(5):320-7. PMC: 3982178. DOI: 10.7150/jca.8748. View

Cortes J, OShaughnessy J, Loesch D, Blum J, Vahdat L, Petrakova K . Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377(9769):914-23. DOI: 10.1016/S0140-6736(11)60070-6. View

Swami U, Chaudhary I, Ghalib M, Goel S . Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2011; 81(2):163-84. PMC: 3954568. DOI: 10.1016/j.critrevonc.2011.03.002. View

Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart M, Cardoso F . Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist. 2007; 12(3):253-70. DOI: 10.1634/theoncologist.12-3-253. View

Li J, Ren J, Sun W . Systematic review of ixabepilone for treating metastatic breast cancer. Breast Cancer. 2016; 24(2):171-179. DOI: 10.1007/s12282-016-0717-0. View

Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K . Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Invest New Drugs. 2017; 35(6):791-799. PMC: 5694520. DOI: 10.1007/s10637-017-0486-4. View

Park Y, Kim T, Im Y, Lee K, Park I, Sohn J . Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Res Treat. 2016; 49(2):423-429. PMC: 5398406. DOI: 10.4143/crt.2016.191. View

Pivot X, Marme F, Koenigsberg R, Guo M, Berrak E, Wolfer A . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016; 27(8):1525-31. PMC: 4959925. DOI: 10.1093/annonc/mdw203. View

Ou-Yang F, Hsu N, Juan C, Huang H, Moi S, Chen F . Breast cancer quality of care in Taiwan in relation to hospital volume: a population-based cohort study. Asia Pac J Clin Oncol. 2015; 11(4):308-13. DOI: 10.1111/ajco.12403. View

10.

Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E . Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. BMC Cancer. 2017; 17(1):819. PMC: 5716387. DOI: 10.1186/s12885-017-3846-8. View

11.

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman P . Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014; 148(3):553-61. PMC: 4243003. DOI: 10.1007/s10549-014-3144-y. View

12.

Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y . A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2011; 23(6):1441-8. DOI: 10.1093/annonc/mdr444. View

13.

Garrone O, Montemurro F, Saggia C, La Verde N, Vandone A, Airoldi M . Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life. Springerplus. 2016; 5:59. PMC: 4720621. DOI: 10.1186/s40064-016-1700-0. View

14.

Watanabe J . Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. Springerplus. 2015; 4:625. PMC: 4627999. DOI: 10.1186/s40064-015-1422-8. View

15.

dOnofrio A, Mazzetta C, Robertson C, Smans M, Boyle P, Boniol M . Maps and atlases of cancer mortality: a review of a useful tool to trigger new questions. Ecancermedicalscience. 2016; 10:670. PMC: 5014559. DOI: 10.3332/ecancer.2016.670. View

16.

Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E . Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii11-9. DOI: 10.1093/annonc/mds232. View

17.

Maeda S, Saimura M, Minami S, Kurashita K, Nishimura R, Kai Y . Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast. 2017; 32:66-72. DOI: 10.1016/j.breast.2016.12.017. View

18.

Kaufman P, Awada A, Twelves C, Yelle L, Perez E, Velikova G . Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015; 33(6):594-601. PMC: 4463422. DOI: 10.1200/JCO.2013.52.4892. View

19.

Towle M, Salvato K, Budrow J, Wels B, Kuznetsov G, Aalfs K . In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001; 61(3):1013-21. View

20.

Visconti R, Grieco D . Fighting tubulin-targeting anticancer drug toxicity and resistance. Endocr Relat Cancer. 2017; 24(9):T107-T117. DOI: 10.1530/ERC-17-0120. View